These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. Thiesen S, Yin P, Jorgensen AL, Zhang JE, Manzo V, McEvoy L, Barton C, Picton S, Bailey S, Brock P, Vyas H, Walker D, Makin G, Bandi S, Pizer B, Hawcutt DB, Pirmohamed M. Pharmacogenet Genomics; 2017 Jun 15; 27(6):213-222. PubMed ID: 28445188 [Abstract] [Full Text] [Related]
34. Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group. Nageswara Rao AA, Wallace DJ, Billups C, Boyett JM, Gajjar A, Packer RJ. Pediatr Blood Cancer; 2014 Jan 15; 61(1):102-6. PubMed ID: 23956184 [Abstract] [Full Text] [Related]
39. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. Clemens E, de Vries AC, Pluijm SF, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer LC, van der Pal HJ, van Grotel M, van den Heuvel-Eibrink MM, DCOG-LATER, The Netherlands. Eur J Cancer; 2016 Dec 15; 69():77-85. PubMed ID: 27821322 [Abstract] [Full Text] [Related]